A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

Background: Fibroblast growth factor 21 (FGF21) has become a promising therapeutic target for metabolic diseases such as type 2 diabetes (T2D), obesity and non-alcoholic steatohepatitis. However, the clinical application of natural FGF21 molecule is limited because of its instability in vitro and sh...

Full description

Bibliographic Details
Main Authors: Qi Pan, Shushan Lin, Yu Li, Liang Liu, Xiaoping Li, Xianglei Gao, Jiangyu Yan, Baohua Gu, Xiaofeng Chen, Wenjia Li, Xinfa Tang, Chao Chen, Lixin Guo
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:EBioMedicine
Subjects:
Diabetes
NASH
FGF21
GLP-1
Fusion protein
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396420305788

Internet

http://www.sciencedirect.com/science/article/pii/S2352396420305788

Similar Items